ArticleClinical and experimental hepatology2021
Metabolic associated fatty liver disease and adverse maternal and fetal outcomes: a systematic review and meta-analysis.
Article in Clinical and experimental hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- MASLD in Pregnancy: Rising Prevalence and Adverse Maternal and Perinatal Outcomes in a National Cohort, 2016-2022.Digestive diseases and sciences · 2026Article
- Towards precise evaluation of steatotic liver disease subtypes and adverse pregnancy outcomes: methodological insights.Hepatology international · 2026Article
- Metabolic-associated fatty liver disease and pregnancy complications: new challenges and clinical perspectives.Therapeutic advances in endocrinology and metabolism · 2024Review
- Article
- Pregnancy and Metabolic-associated Fatty Liver Disease: A Clinical Update.Journal of clinical and translational hepatology · 2022Review
- Metabolic dysfunction-associated steatotic liver disease: Emerging risk factors for adverse pregnancy outcomes.Clinical liver diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aim of the studyMetabolic-associated fatty liver disease (MAFLD) is now the most prevalent chronic liver disease in the world. Its prevalence in women of reproductive age is approximately 10%. Due to its high prevalence in this specific population, it is important to investigate adverse maternal and fetal outcomes caused by MAFLD during pregnancy. We aimed to summarize the association between MAFLD and adverse maternal and fetal outcomes. MATERIAL AND
methodsA search was conducted on PubMed and ProQuest from inception to April 1, 2021, for studies assessing the association between MAFLD and adverse maternal and fetal outcomes. The quality of included studies was assessed using the Newcastle-Ottawa scale (NOS). We analyzed the pooled odds ratios (ORs) with 95% confidence intervals (CIs) using a fixed and random-effects model. Heterogeneity was assessed using
resultsSix studies comprising 20,535,994 (5,964 MAFLD) pregnant women were included. The quality of studies ranged from 6 to 8 stars. MAFLD was significantly associated with increased risk of dysglycemia (OR = 3.65, 95% CI = 2.47-5.39), pregnancy-associated hypertension (OR = 3.27, 95% CI = 2.75-3.88), cesarean section (OR = 2.78, 95% CI = 1.60-4.83), and preterm birth (OR = 1.70, 95% CI = 1.37-2.10) but not large for gestational age (OR = 1.69, 95% CI = 0.64-4.45).
conclusionsThe presence of MAFLD is associated with adverse maternal and fetal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.